Core Viewpoint - Heng Rui Medicine has received a confirmation letter from the FDA regarding the acceptance of its Biologics License Application (BLA) for injection of Carrelizumab combined with Apatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma patients [1] Group 1 - The FDA has accepted the BLA submitted by Heng Rui Medicine for Carrelizumab [1] - The target review date set by the FDA under the Prescription Drug User Fee Act (PDUFA) is July 23, 2026 [1]

恒瑞医药公告称，公司于2025年8月20日起实施股份回购计划，预计金额10亿元 - 20亿元，用于员工持 股计划或股权激励。截至2026年1月31日，累计回购股份978.84万股，占总股本0.15%，已支付总金额 64,628.87万元，回购价格区间为56.10 - 70.00元/股。2026年1月回购88.97万股，占总股本0.013%，支付 5,107.24万元。 ...

Core Viewpoint - AI is revolutionizing the life sciences and pharmaceutical research, significantly improving efficiency and reducing costs associated with drug development [3][4][7]. Group 1: Global AI Medical Market Expansion - The global AI medical market is rapidly expanding, characterized by the entry of major tech companies like NVIDIA, Google, and Microsoft, which are restructuring medical infrastructure [3][4]. - AI technology is deeply integrating with biotechnology, leading to unprecedented levels of financing and mergers in the AI medical sector, with projections indicating a record high in 2025 [4][5]. - Major pharmaceutical companies are investing billions in partnerships with AI startups, exemplified by Sanofi's $2.5 billion collaboration with Earendil and other significant deals with Atomwise and Dren Bio [5][6]. Group 2: AI Drug Development and Applications - AI is transforming drug development by addressing various diseases, including cancer, neurodegenerative diseases, metabolic disorders, autoimmune diseases, infectious diseases, and rare diseases, significantly lowering trial costs and improving success rates [7][8][9]. - The efficiency of AI in drug development is highlighted by its ability to reduce the traditional 10-year, $1 billion timeline with only a 10% success rate, enhancing the overall drug discovery process [8][9]. - AI's role in drug discovery is expanding from initial target identification to clinical trial design and patient recruitment, covering the entire industry spectrum [8][9]. Group 3: Policy Support for AI in Healthcare - National strategies are being implemented to support AI applications in healthcare, including the 2025 guidelines promoting AI in drug development to reduce costs and time [9][10]. - Local governments are providing financial incentives for AI drug development, with subsidies for computational costs and support for companies achieving regulatory approvals [11][12]. - Policies are encouraging the internationalization of innovative drugs, with significant support for local companies conducting global clinical trials [11][12]. Group 4: Future Opportunities in AI Healthcare - The first major opportunity lies in AI-assisted drug discovery, which is expected to have a trillion-dollar market potential, particularly in treating diseases like cancer and Alzheimer's [25][26]. - AI is set to enhance diagnostic accuracy in medical imaging, addressing resource distribution issues and integrating diagnostic capabilities into imaging devices [28][29]. - AI will drive advancements in clinical decision support and healthcare information systems, improving data utilization and patient care efficiency [30][31]. - AI-powered surgical robots are expected to redefine surgical precision and enable remote medical procedures, breaking geographical barriers in healthcare delivery [32][33].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of February 1, 2026 [1] Core Insights - The competitiveness of China's active pharmaceutical ingredient (API) exports is supported by technological advancements, with a focus on supply variables [2] - Significant transactions in the industry highlight the ongoing validation of clinical data for innovative drugs, with multiple major deals occurring in early 2026 [3] - Leading companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [4] - A new pricing system for GLP-1 drugs is forming domestically, while the oral GLP-1 market is rapidly expanding in the U.S. [5] - The market value of oral autoimmune drugs is gaining attention, with promising results from key clinical trials [6] Summary by Sections Industry Overview - In 2025, China's pharmaceutical and healthcare product exports reached $111.34 billion, growing by 3.14%, with API exports accounting for $42.87 billion, representing 76.8% of total Western medicine exports [2] - The report notes a 10.6% decline in pharmaceutical exports to the U.S. due to tariff impacts, while the EU and emerging markets saw increases of 11.38% and 4.49%, respectively [2] Major Transactions and Innovations - In January 2026, a significant licensing agreement between CSPC Pharmaceutical and AstraZeneca was announced, involving a $1.2 billion upfront payment and potential milestone payments totaling up to $3.5 billion [3] - The report emphasizes the need for continuous clinical data validation for authorized products to secure future milestone payments [3] Small Nucleic Acid Developments - Leading companies like China Biologic Products are acquiring innovative firms in the small interfering RNA (siRNA) sector, indicating a strategic focus on this area [4] - The report highlights successful clinical trial results for small nucleic acid drugs, which are attracting more attention from major pharmaceutical companies [4] GLP-1 Market Dynamics - A new pricing structure for GLP-1 products is emerging in China, with the anticipated launch of generic versions expected to further influence market prices [5] - The report notes that oral GLP-1 drugs are gaining traction in the U.S., with significant prescription numbers reported shortly after launch [5] Oral Autoimmune Drug Developments - Takeda's new oral TYK2 inhibitor has shown positive results in key clinical trials for psoriasis, indicating a potential breakthrough in oral autoimmune treatments [6] - The report mentions ongoing developments in oral autoimmune drugs targeting various pathways, with several domestic companies advancing their clinical trials [6] Stock Recommendations - The report suggests focusing on companies that are likely to benefit from the API cycle reversal, such as Chuan Ning Biological and Guobang Pharmaceutical, and highlights the potential of small nucleic acid drugs and oral autoimmune treatments [8]

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [4][10][13]. Core Insights - The report continues to recommend the innovative pharmaceutical and medical device industry chain, including a list of A-share and H-share stocks with an "Overweight" rating [2][10][13]. - In January 2026, the pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index rising by 3.8% while the SW Pharmaceutical and Biological Index increased by 3.1% [15][24]. - The report highlights that the medical services, chemical raw materials, and medical devices sub-sectors performed relatively well, with increases of 8.8%, 5.6%, and 5.3% respectively [19][24]. - The report notes that the A-share pharmaceutical sector's premium level is currently at a normal level, with a relative premium rate of 61.1% as of the end of January 2026 [21][26]. Summary by Sections 1. Continued Recommendation for Innovative Pharmaceutical and Medical Device Industry - The report maintains an "Overweight" rating for the following A-share stocks: Hengrui Medicine, Kelun Pharmaceutical, Xinlitai, BeiGene, Teru Biopharma, Jingxin Pharmaceutical, Yifang Biopharma, WuXi AppTec, Kailai Pharmaceutical, Tigermed, Lepu Medical, United Imaging, Microelectrophysiology, and Tongce Medical, and includes these stocks in the February 2026 monthly portfolio [10][12][13]. 2. January 2026 Pharmaceutical Sector Performance - The report states that the pharmaceutical sector underperformed the market in January 2026, with the SW Pharmaceutical and Biological Index ranking 18th among the Shenwan first-level industries [15][16][24]. 3. January 2026 Performance of Hong Kong and US Pharmaceutical Sectors - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare Index rising by 8.6% and the biotechnology sector by 8.5%, compared to a 6.9% increase in the Hang Seng Index [24]. - Conversely, the US pharmaceutical sector underperformed, with the S&P Healthcare Select Sector Index declining by 0.3% while the S&P 500 rose by 1.4% [24].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [4][10][13]. Core Insights - The report continues to recommend the innovative pharmaceutical and medical device industry chain, including a list of A-share and H-share stocks with an "Overweight" rating [2][10][13]. - In January 2026, the pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index rising by 3.8% while the SW Pharmaceutical and Biological Index increased by 3.1% [15][19]. - The report highlights that the medical services, chemical raw materials, and medical devices sub-sectors performed relatively well, with increases of 8.8%, 5.6%, and 5.3% respectively [19][24]. - The report notes that the A-share pharmaceutical sector currently has a premium level of 61.1% compared to the overall A-share market [21][26]. Summary by Sections 1. Continued Recommendation for Innovative Pharmaceutical and Medical Device Industry - The report maintains an "Overweight" rating for the following A-share stocks: Hengrui Medicine, Kelun Pharmaceutical, Xinlitai, BeiGene, Teva Pharmaceutical, Jingxin Pharmaceutical, Yifang Biotechnology, WuXi AppTec, Kailai Pharmaceutical, Tigermed, Lepu Medical, United Imaging Healthcare, Microelectronic Physiology, and Tongce Medical [10][11][12]. - The report also maintains an "Overweight" rating for the following H-share stocks: Hansoh Pharmaceutical, 3SBio, Kelun Biotech, CanSino Biologics, and BeiGene [13]. 2. January 2026 Pharmaceutical Sector Performance - The report indicates that the pharmaceutical sector's performance was weaker than the market, ranking 18th among the Shenwan first-level industries [15][16]. - The report provides details on individual stock performances, with the top gainers being Hongbo Pharmaceutical (+61.4%), Baolai Technology (+55.2%), and Hualan Biological (+51.7%) [21]. 3. January 2026 Hong Kong and US Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare Index rising by 8.6% and the Hang Seng Biotechnology Index by 8.5% [24]. - In contrast, the US pharmaceutical sector underperformed, with the S&P Healthcare Select Sector Index declining by 0.3% [24].

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the continuous focus on investment opportunities related to AI in healthcare, driven by the growth of Tencent's AI applications and the need for data-driven solutions in medical settings [2][21]. - The investment logic centers around "data closed-loop" and "scene demand," highlighting AI's role as a core productivity driver in healthcare under the dual pressures of cost control and technological advancements [22]. - The report outlines a three-stage clinical value investment strategy, focusing on innovative drug chains and medical devices, with specific recommendations for companies in these sectors [3][27]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index fell by 3.31%, underperforming the CSI 300 index by 3.39 percentage points and ranking 22nd among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index also declined by 2.98%, lagging behind the Hang Seng Index by 4.69 percentage points [1][15]. R&D Progress - Recent developments include new drug applications from companies such as Hengrui Medicine and Innovent Biologics, with ongoing clinical trials for various products [30]. Key Companies and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, recommending "Buy" for several firms including Innovent Biologics, WuXi AppTec, and Mindray Medical [4][27]. AI Healthcare Investment Focus - The report identifies several core areas for AI in healthcare, including AI drug development, medical imaging, chronic disease management, and surgical robotics, emphasizing the importance of proprietary data and business scenarios for competitive advantage [22][24]. Annual Investment Strategy - The report suggests that the investment focus should increasingly emphasize the clinical value of pharmaceuticals, with a positive outlook on innovative drug chains and high-end medical devices [3][26].

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector, with a focus on companies such as Haoyuan Pharmaceutical and Aopumai [1]. Core Insights - The pharmaceutical sector is experiencing a recovery driven by multiple factors, including interest rate cuts, which support the continuous revival of upstream research and development [1]. - The A-share pharmaceutical index has shown a year-to-date increase of 3.14%, outperforming the CSI 300 index by 2.51% [4]. - The report emphasizes the importance of early-stage research projects, with pharmaceutical companies increasingly prioritizing these initiatives due to improved funding conditions and heightened enthusiasm for innovative drug development [4][16]. Summary by Sections Industry Performance - The A-share pharmaceutical index has decreased by 3.31% this week, while the Hang Seng Biotechnology Index has decreased by 3.24% [4][9]. - The report highlights that the pharmaceutical commercial sector has seen a significant decline of 4.49%, while traditional Chinese medicine and biological products have experienced smaller declines [4][9]. Research and Development Progress - The report outlines that there is a growing emphasis on innovative drug development across various sectors, including generic drug companies and traditional Chinese medicine enterprises [16]. - Notable advancements include Roche's submission of Giredestrant for approval in the U.S. for HR+/HER2- advanced breast cancer, and Relay Therapeutics' submission for a potential first-in-class therapy for cholangiocarcinoma [4]. Recommended Companies - The report suggests focusing on companies in the life sciences service sector, particularly those benefiting from early-stage research demand, mergers and acquisitions, and commercial production partnerships [4][12]. - Specific companies highlighted for investment include: - Haoyuan Pharmaceutical - Baidu Pharmaceutical - Aopumai - YaoKang Biotechnology - Nanwei Technology - Aladdin [4][12]. Market Trends - The report notes that the global pharmaceutical R&D expenditure continues to grow, with an increase in the number of new pipelines and a sustained interest in innovative drug development [18]. - The report also mentions that the easing of IPO regulations has led to a resurgence in the number of biopharmaceutical companies seeking to go public, further stimulating demand in the life sciences sector [17].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, with a focus on companies like Haoyuan Pharmaceutical and Aopumai [1]. Core Insights - The report highlights a recovery in the upstream research sector supported by interest rate cuts and other factors, indicating a renewed focus on early-stage research projects by pharmaceutical companies [4][16]. - The A-share pharmaceutical index has shown a year-to-date increase of 3.14%, outperforming the CSI 300 index by 2.51% [4]. - The report emphasizes the importance of innovation in drug development, particularly in early-stage projects, and suggests that the demand for life sciences services will increase as funding becomes more available [4][16]. Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 3.31% this week, while the Hang Seng Biotechnology Index has decreased by 3.24% [4][9]. - The report notes that the pharmaceutical sector is experiencing a rebound in demand, driven by both domestic and international factors, including a resurgence in IPOs and funding opportunities [16][18]. Research and Development Progress - The report details significant advancements in innovative drugs and improved drugs, with several companies submitting applications for new drug approvals [20]. - Companies like Roche and Relay Therapeutics are making strides in clinical trials, with Roche submitting an application for Giredestrant for breast cancer treatment [4][20]. Recommended Stocks - The report suggests focusing on specific companies based on sub-industry strengths, including: - CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, Aopumai, and King’s Ray Biotechnology [12]. - Traditional Chinese medicine: Jichuan Pharmaceutical, Zuoli Pharmaceutical, and Fangsheng Pharmaceutical [12]. - PD1 PLUS: 3SBio, Kangfang Biotech, and Innovent Biologics [12]. - ADC: InnoCare Pharma and Kelun-Biotech [12]. - AI drug development: Jingtaikong Holdings [12].

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [12][60]. Core Insights - The report highlights significant collaborations in the innovative drug sector, including 石药集团 (Shijiazhuang Yiling Pharmaceutical) partnering with AstraZeneca for long-acting peptide drug development and receiving clinical trial approval for SYS6055 injection in China [8][37]. - The report emphasizes the robust R&D capabilities of Chinese pharmaceutical companies showcased at the 2026 JPM Healthcare Conference, suggesting investment opportunities in innovative drugs, CXO, and upstream life sciences [12][60]. - The report notes the recent release of the revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China," which aims to enhance drug innovation and regulatory processes [19][20]. Industry Data - As of January 29, 2026, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) is 51.60 times, with a valuation premium of 259% relative to the CSI 300 index [10][52]. - The report provides current prices for vitamin raw materials, with Vitamin B1 at 237.5 RMB/kg and Vitamin D3 at 130 RMB/kg, remaining stable compared to January 28 [22]. - The Chinese herbal medicine market index shows a decline of 15% year-on-year, with specific herbs like 党参 (Codonopsis) and 当归 (Angelica) experiencing price drops of 41% and 29% respectively [26]. Company Announcements - 先声药业 (Xiansheng Pharmaceutical) signed an exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, with potential milestone payments reaching up to 1.016 billion euros [36]. - 恒瑞医药 (Hengrui Medicine) received acceptance for a drug listing application and clinical trial approval for multiple products, including a breakthrough therapy designation for HRS-5346 [39][40]. - 诺诚健华 (Innovent Biologics) anticipates a revenue of approximately 2.365 billion RMB for 2025, marking a 134% year-on-year increase [41].